Jubilant Ingrevia Ltd Q2 FY2025 Concall Summary

Key Takeaways

• CDMO breakthrough quarter: Two contracts signed, including a landmark \$300 mn+ five-year agrochemical deal, validating the China-plus-one thesis and the company's platform depth.
• Specialty and Nutrition drove the beat: Specialty Chemicals EBITDA jumped 26% YoY on 25% volume growth, while Nutrition EBITDA rose 29% YoY on a favorable mix shift toward human-grade Niacinamide.
• The mix shift is accelerating: Management now targets Specialty + Nutrition revenue share at north of 75% (from ~60% today), with nearly all future capex directed there, while the acetyl business becomes a smaller, cash-generative anchor.
• A capex cycle is starting, funded from the balance sheet: A ₹2,000–2,500 crore Wave-II capex plan over three years will target CDMO, fine chemicals, and specialty nutrition, with debt kept below ₹900–1,000 crore and coverage under 1.4x.
• What to watch next quarter: Conversion of the 100+ CDMO opportunity pipeline into firm orders, the ramp-up of food-grade Niacinamide and choline volumes, and any sustained uptick in acetic anhydride utilization beyond the current ~70%.

The CDMO Inflection

Two contracts landed in a single quarter, one of them described as among the largest CDMO deals in Indian agrochemicals. Both are with multinational innovators, both involve proprietary intermediates, and both signal that the structural shift away from China is moving from enquiry to signed contract.

• Pipeline depth: Management has held 120+ customer meetings and built a pipeline of 100+ opportunities across pharma, agrochemicals, cosmetics, and semiconductors. The two signed contracts are characterized as "only the tip of the iceberg."
• Execution timelines vary by molecule fit: A CDMO order that fits an existing plant can be executed in 3–6 months; one requiring a new plant or significant modification takes 12+ months. The company is building a multipurpose plant ahead of demand to shorten this window for suitable molecules.
• Competitive moat in CDMO: Backward integration across seven or eight product platforms, cost competitiveness, ESG credentials (EcoVadis, Dow Jones ranking, WEF Green Lighthouse), digitally enabled plants, and a demonstrated willingness to invest capex ahead of revenue combine to make Jubilant a strong contender for India-bound outsourcing.

Deepak Jain: "These two contracts, these are only the tip of the iceberg in terms of the number of such opportunities we expect to catch and realize in the coming years."

Specialty Chemicals: Volume Engine Firing

The segment delivered 13% YoY revenue growth and 26% EBITDA growth, with EBITDA margins touching almost 20%. Underlying volume growth was close to 25%, with price declines versus the prior year shaving off part of the reported revenue growth. Growth was broad-based across pyridine building blocks, pyridine derivatives, diketene derivatives, and microbial products.

• Pyridine and picolines: Material YoY growth driven by higher volumes; agrochemical destocking is largely over and volumes are returning. Prices are largely stable with slight increases in certain segments.
• Diketene derivatives: The second product in the diketene chain is expected to reach 50%+ utilization within this quarter or the next.
• Fine chemicals: Notable QoQ and YoY volume increases in the high-margin fine chemicals portfolio, supported by steady pharma demand and stable pricing.
• Agrochemical recovery: Gradual but visible; excess inventory has cleared and pyridine-based product volumes are recovering. Management expects the steady recovery to continue over coming quarters.
• China pricing: Import prices from China appear to have bottomed out, with a largely flat trend over recent months and even an uptick in certain product segments.

Nutrition & Health Solutions: Mix-Driven Margin Expansion

Revenue grew 12% YoY and EBITDA jumped 29% YoY, driven by higher volumes of both animal and human-grade Niacinamide, elevated Niacinamide pricing, and a favorable shift in volume mix toward human-grade products. Lean initiatives and optimized input costs added further support.

• Niacinamide pricing improved significantly during the quarter, with volumes on an upward trend.
• GMP-compliant facility for food and cosmetic grade Vitamin B3 is set to commission in Q3 FY25; management reports strong customer interest in booking advance volumes.
• Choline dynamics are split: Animal feed-grade choline volumes are holding up but pricing remains under pressure from imports. Food-grade and human-nutrition choline products (choline chloride and choline bitartrate), launched in prior quarters, are gaining traction: customer audits are complete and volumes are expected to pick up in coming months.
• Market position: Jubilant is the #1 global player in Pyridine and Picolines, the only scaled non-Chinese player, and a top-two player in feed-grade Niacinamide. It has maintained market share in Acetic Anhydride across both Indian and European markets in H1 FY25.

Chemical Intermediates: Stabilizing, Not Growing

Quarterly revenue rose 5% QoQ on improved volumes of Ethyl Acetate and Acetic Anhydride, and EBITDA improved 13% QoQ from higher volumes and cost-saving initiatives, partially offset by rising ocean freight costs. YoY performance declined, mainly due to lower prices.

• Acetic Anhydride utilization is running at ~70%, pressured by low demand from the paracetamol segment, where most customers are operating plants at suboptimal capacities. Management hopes to lift utilization as markets improve.
• Strategic role going forward: The acetyl business will see its relative revenue share continue to decline as Specialty and Nutrition grow toward a combined 75%+ share. Nearly 100% of incremental capex will flow to Specialty and the specialty portion of Nutrition.

China-Plus-One: From Enquiry to Contract

Every customer met during roadshows in Japan, Europe, the US, China, and India talked about diversifying from China. The two CDMO contracts, both in agrochemicals and signed during a market downturn, are cited as the strongest proof that the trend is converting into real business.

• Bio Secure Act and US election expectations are expected to accelerate outsourcing to India across pharma, agrochemicals, cosmetics, and semiconductors.
• Customer urgency is high: Innovators face pressure to move quickly, and Jubilant's willingness to invest capex ahead of revenue positions it to capture that urgency.
• Export growth rose 30% YoY, with the European Union and Japan driving the increase.

Deepak Jain: "It's important not just for my P&L and balance sheet, it's important for my customers' P&L even more because they wanted the products yesterday and they are coming to us now because of this pressure coming to them."

Capital Allocation & the Pinnacle 345 Path

Management reaffirmed the Pinnacle 345 aspiration: 3x revenue and 4x EBITDA over five years from an FY24 base of ₹4,200 crore, though the timeline may shift by a couple of quarters depending on agrochemical recovery and pricing assumptions.

• Wave-II capex: ₹2,000–2,500 crore over the next three years, directed entirely at Specialty Chemicals and the specialty portion of Nutrition. Specific areas include CDMO (agro and pharma), fine chemicals via a multipurpose plant, and human/cosmetic-grade nutrition products.
• Funding: Incremental capex will be funded from internal accruals and EBITDA. Debt may rise marginally but will not exceed ₹900–1,000 crore, with a coverage ratio kept under 1.4x.
• Diketene ambition: The company aspires to become a global leader in diketene and will create a multipurpose plant to expand its derivatives portfolio.

Deepak Jain: "Every decision we take at Ingrevia from an investment perspective, the minimum threshold for us is 20% EBITDA and 20% ROCE. So, we have applied the same filters and same screens as finalize the commercial construct of this contact as well."

Guidance & Commitments

Key Metrics